Glow-in-the-Dark dye could help surgeons spot hidden breast cancer cells

NCT ID NCT05130801

Recruiting now Diagnosis Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a new imaging agent called pHLIP ICG that makes breast cancer cells glow during surgery. The goal is to help surgeons see and remove all cancerous tissue more accurately. The trial involves 55 adults with early-stage breast cancer who have not had prior treatment. It is the first human test of this agent, so safety is a key focus.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pHLIP ICG (a fluorescent imaging agent)
What this could lead to: If successful, this could help surgeons remove breast cancer more completely during surgery by highlighting cancerous tissue that might otherwise be missed.
What could go wrong: This is an early-phase trial (Phase I/IIa) testing the safety and effectiveness of pHLIP ICG for the first time in humans. It may not improve surgical outcomes, and there are risks of side effects from the imaging agent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Memorial Sloan Kettering Bergen (All Protocol Activities)
RECRUITING

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITING

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.